Get Started

Artificial Intelligence | Machine Learning | Machine Perception Immunai | Decoding the Immune System to Improve Health

Consumer, Immunology, Healthcare, Biotechnology, Genomic Technologies New York, NY, United States

Artificial Intelligence | Machine Learning | Machine Perception

Immunai | Decoding the Immune System to Improve Health

Immunology, Healthcare, Biotechnology, Genomic Technologies

New York, NY, United States

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes

Immunai’s end-to-end single-cell platform enables high resolution profiling of the immune system at industrial scale, generating biological insights that accelerate R&D and power novel discoveries

Total Funding: $20,000,000

Funding Stage: Seed

Business Stage: Launched

Market: B2C, B2B

Company Size: 26 to 50

Founded: 2019

Date

Round

$ Raised

Investors

10/28/2021

Series B

$215M

8VC, Icon Ventures, Piedmont Capital

Date : 10/28/2021

Round: Series B

$ Raised: $215M

Investors: 8VC, Icon Ventures, Piedmont Capital

For AI/ML Startup Founders

Get introduced to VC/PE/CVC investors

Signup and Get Started

For Investors at VC/PE firms

Get introduced to AI/ML Startup founders or founders at Immunai

Noam Solomon
CEO

Daniel Wells
Co-Founder

Immunai - Manage Profile

Immunai is growing. Want to work at Immunai? Immunai is hiring. Join team at Immunai

World's Most Promising AI/ML Startups